PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34856202-4 2022 beta-Caryophyllene (BCP) is a low-efficacy natural agonist of CB2 and a common constituent of human diet with well-established anti-inflammatory properties. caryophyllene 0-18 cannabinoid receptor 2 Homo sapiens 62-65 33809114-4 2021 Among them, we focused on the natural sesquiterpene and cannabinoid type 2 (CB2) receptor agonist Trans-beta-caryophyllene (BCP) by analyzing its role in enhancing glucose metabolism in skeletal muscle cells. caryophyllene 98-122 cannabinoid receptor 2 Homo sapiens 56-74 33809114-4 2021 Among them, we focused on the natural sesquiterpene and cannabinoid type 2 (CB2) receptor agonist Trans-beta-caryophyllene (BCP) by analyzing its role in enhancing glucose metabolism in skeletal muscle cells. caryophyllene 98-122 cannabinoid receptor 2 Homo sapiens 76-79 33809114-4 2021 Among them, we focused on the natural sesquiterpene and cannabinoid type 2 (CB2) receptor agonist Trans-beta-caryophyllene (BCP) by analyzing its role in enhancing glucose metabolism in skeletal muscle cells. caryophyllene 124-127 cannabinoid receptor 2 Homo sapiens 56-74 33809114-4 2021 Among them, we focused on the natural sesquiterpene and cannabinoid type 2 (CB2) receptor agonist Trans-beta-caryophyllene (BCP) by analyzing its role in enhancing glucose metabolism in skeletal muscle cells. caryophyllene 124-127 cannabinoid receptor 2 Homo sapiens 76-79 33809114-9 2021 Our results show that in myotubes, BCP significantly enhances glucose uptake, glycolytic and oxidative pathways, and ATP synthesis through a CB2-dependent mechanism. caryophyllene 35-38 cannabinoid receptor 2 Homo sapiens 141-144 34856202-4 2022 beta-Caryophyllene (BCP) is a low-efficacy natural agonist of CB2 and a common constituent of human diet with well-established anti-inflammatory properties. caryophyllene 20-23 cannabinoid receptor 2 Homo sapiens 62-65 34856202-8 2022 Experiments established the dose-response effects of BCP and pharmacological mechanisms of the antinociceptive action dependent on CB2 and opioid receptors. caryophyllene 53-56 cannabinoid receptor 2 Homo sapiens 131-134 35056767-5 2022 Applying our novel algorithm toolset-MCCS, we docked three known AMs of CB2 including Ec2la (C-2), trans-beta-caryophyllene (TBC) and cannabidiol (CBD) to each site for further comparisons and quantified the potential binding residues in each allosteric binding site. caryophyllene 99-123 cannabinoid receptor 2 Homo sapiens 72-75 35056767-5 2022 Applying our novel algorithm toolset-MCCS, we docked three known AMs of CB2 including Ec2la (C-2), trans-beta-caryophyllene (TBC) and cannabidiol (CBD) to each site for further comparisons and quantified the potential binding residues in each allosteric binding site. caryophyllene 125-128 cannabinoid receptor 2 Homo sapiens 72-75 33114208-6 2020 In Epac1-CB2-HEK293 responder cells, the terpenoid beta-caryophyllene significantly modified the cAMP response through CB2. caryophyllene 51-69 cannabinoid receptor 2 Homo sapiens 9-12 33579467-0 2021 beta-Caryophyllene nanoparticles design and development: Controlled drug delivery of cannabinoid CB2 agonist as a strategic tool towards neurodegeneration. caryophyllene 0-18 cannabinoid receptor 2 Homo sapiens 97-100 34054510-7 2021 To pharmacologically activate the CB2 receptors, a naturally occurring cannabinoid ligand, beta-caryophyllene (BCP), received attention due to its potent anti-inflammatory, antiviral, and immunomodulatory properties. caryophyllene 91-109 cannabinoid receptor 2 Homo sapiens 34-37 34054510-7 2021 To pharmacologically activate the CB2 receptors, a naturally occurring cannabinoid ligand, beta-caryophyllene (BCP), received attention due to its potent anti-inflammatory, antiviral, and immunomodulatory properties. caryophyllene 111-114 cannabinoid receptor 2 Homo sapiens 34-37 33114208-6 2020 In Epac1-CB2-HEK293 responder cells, the terpenoid beta-caryophyllene significantly modified the cAMP response through CB2. caryophyllene 51-69 cannabinoid receptor 2 Homo sapiens 119-122 32560286-0 2020 beta-Caryophyllene Reduces the Inflammatory Phenotype of Periodontal Cells by Targeting CB2 Receptors. caryophyllene 0-18 cannabinoid receptor 2 Homo sapiens 88-91 32560286-3 2020 The aim of this study was to evaluate the therapeutic potential of beta-Caryophyllene (BCP), a CB2 agonist, in an in vitro model of oral mucositis. caryophyllene 67-85 cannabinoid receptor 2 Homo sapiens 95-98 32560286-3 2020 The aim of this study was to evaluate the therapeutic potential of beta-Caryophyllene (BCP), a CB2 agonist, in an in vitro model of oral mucositis. caryophyllene 87-90 cannabinoid receptor 2 Homo sapiens 95-98 32560286-7 2020 BCP blunted the LPS-induced inflammatory phenotype and this effect was reverted by the CB2 antagonist AM630. caryophyllene 0-3 cannabinoid receptor 2 Homo sapiens 87-90 32340197-0 2020 beta-Caryophyllene Inhibits Cell Proliferation through a Direct Modulation of CB2 Receptors in Glioblastoma Cells. caryophyllene 0-18 cannabinoid receptor 2 Homo sapiens 78-81 32340197-2 2020 b-caryophyllene (BCP) is a cannabinoid receptor 2 (CB2) agonist that showed an important anti-inflammatory effect through the interaction of CB2 and peroxisome proliferator-activated receptor gamma (PPARg) receptors. caryophyllene 0-15 cannabinoid receptor 2 Homo sapiens 27-49 32340197-2 2020 b-caryophyllene (BCP) is a cannabinoid receptor 2 (CB2) agonist that showed an important anti-inflammatory effect through the interaction of CB2 and peroxisome proliferator-activated receptor gamma (PPARg) receptors. caryophyllene 0-15 cannabinoid receptor 2 Homo sapiens 51-54 32340197-2 2020 b-caryophyllene (BCP) is a cannabinoid receptor 2 (CB2) agonist that showed an important anti-inflammatory effect through the interaction of CB2 and peroxisome proliferator-activated receptor gamma (PPARg) receptors. caryophyllene 0-15 cannabinoid receptor 2 Homo sapiens 141-144 30652534-5 2020 After docking of known negative CB2 allosteric modulators (NAMs), dihydro-gambogic acid (DHGA) and trans-beta-caryophyllene (TBC) (note that TBC also shows agonist activity), at the predicted allosteric sites, the best total complex with CB2, CP55,940 and NAM was embedded into a hydrated lipid bilayer and subjected to a 200 ns MD simulation. caryophyllene 99-123 cannabinoid receptor 2 Homo sapiens 32-35 30652534-5 2020 After docking of known negative CB2 allosteric modulators (NAMs), dihydro-gambogic acid (DHGA) and trans-beta-caryophyllene (TBC) (note that TBC also shows agonist activity), at the predicted allosteric sites, the best total complex with CB2, CP55,940 and NAM was embedded into a hydrated lipid bilayer and subjected to a 200 ns MD simulation. caryophyllene 141-144 cannabinoid receptor 2 Homo sapiens 32-35 30652534-5 2020 After docking of known negative CB2 allosteric modulators (NAMs), dihydro-gambogic acid (DHGA) and trans-beta-caryophyllene (TBC) (note that TBC also shows agonist activity), at the predicted allosteric sites, the best total complex with CB2, CP55,940 and NAM was embedded into a hydrated lipid bilayer and subjected to a 200 ns MD simulation. caryophyllene 141-144 cannabinoid receptor 2 Homo sapiens 238-241 31862467-3 2020 beta-Caryophyllene (BCP) is a CB2 agonist that exhibited anti-inflammatory, analgesic effects but minimal psychoactive effects. caryophyllene 0-18 cannabinoid receptor 2 Homo sapiens 30-33 31862467-3 2020 beta-Caryophyllene (BCP) is a CB2 agonist that exhibited anti-inflammatory, analgesic effects but minimal psychoactive effects. caryophyllene 20-23 cannabinoid receptor 2 Homo sapiens 30-33 31862467-8 2020 Also BCP improved the stress-related changes in the hippocampal expression of COX-2, BDNF, and CB2 receptor expression. caryophyllene 5-8 cannabinoid receptor 2 Homo sapiens 95-98 30652534-5 2020 After docking of known negative CB2 allosteric modulators (NAMs), dihydro-gambogic acid (DHGA) and trans-beta-caryophyllene (TBC) (note that TBC also shows agonist activity), at the predicted allosteric sites, the best total complex with CB2, CP55,940 and NAM was embedded into a hydrated lipid bilayer and subjected to a 200 ns MD simulation. caryophyllene 99-123 cannabinoid receptor 2 Homo sapiens 238-241 30652534-5 2020 After docking of known negative CB2 allosteric modulators (NAMs), dihydro-gambogic acid (DHGA) and trans-beta-caryophyllene (TBC) (note that TBC also shows agonist activity), at the predicted allosteric sites, the best total complex with CB2, CP55,940 and NAM was embedded into a hydrated lipid bilayer and subjected to a 200 ns MD simulation. caryophyllene 125-128 cannabinoid receptor 2 Homo sapiens 32-35 30529211-4 2019 beta-Caryophyllene (BCP) is a selective type 2 cannabinoid (CB2) receptor agonist. caryophyllene 0-18 cannabinoid receptor 2 Homo sapiens 60-63 30620895-3 2019 beta-Caryophyllene (BCP) is a dietary selective CB2 agonist, which deserves the anti-inflammatory and antioxidant effects at both low and high doses through activation of the CB2 receptor. caryophyllene 0-18 cannabinoid receptor 2 Homo sapiens 48-51 30620895-3 2019 beta-Caryophyllene (BCP) is a dietary selective CB2 agonist, which deserves the anti-inflammatory and antioxidant effects at both low and high doses through activation of the CB2 receptor. caryophyllene 0-18 cannabinoid receptor 2 Homo sapiens 175-178 30620895-3 2019 beta-Caryophyllene (BCP) is a dietary selective CB2 agonist, which deserves the anti-inflammatory and antioxidant effects at both low and high doses through activation of the CB2 receptor. caryophyllene 20-23 cannabinoid receptor 2 Homo sapiens 48-51 30620895-3 2019 beta-Caryophyllene (BCP) is a dietary selective CB2 agonist, which deserves the anti-inflammatory and antioxidant effects at both low and high doses through activation of the CB2 receptor. caryophyllene 20-23 cannabinoid receptor 2 Homo sapiens 175-178 30620895-6 2019 Moreover, we showed that BCP exerts its effects through CB2 receptors which overproduction of ceramides by SMase at middle to higher concentrations of BCP reduce the protective activity of BCP and results in the activation of the PPAR-gamma pathway. caryophyllene 25-28 cannabinoid receptor 2 Homo sapiens 56-59 30620895-6 2019 Moreover, we showed that BCP exerts its effects through CB2 receptors which overproduction of ceramides by SMase at middle to higher concentrations of BCP reduce the protective activity of BCP and results in the activation of the PPAR-gamma pathway. caryophyllene 151-154 cannabinoid receptor 2 Homo sapiens 56-59 30620895-6 2019 Moreover, we showed that BCP exerts its effects through CB2 receptors which overproduction of ceramides by SMase at middle to higher concentrations of BCP reduce the protective activity of BCP and results in the activation of the PPAR-gamma pathway. caryophyllene 151-154 cannabinoid receptor 2 Homo sapiens 56-59 30529211-4 2019 beta-Caryophyllene (BCP) is a selective type 2 cannabinoid (CB2) receptor agonist. caryophyllene 20-23 cannabinoid receptor 2 Homo sapiens 60-63 30529211-9 2019 Also, we demonstrated that BCP"s protective effects against LPS-induced oligodendrocytes toxicity were mediated via the CB2 receptor through different pathways including Nrf2/HO-1/anti-oxidant axis, and PPAR-gamma, at low (0.2 and 1 microM), and high (10-50 microM) concentrations, respectively. caryophyllene 27-30 cannabinoid receptor 2 Homo sapiens 120-123 30026695-13 2018 Conclusion: The common food additive and CB2 agonist beta-caryophyllene might have the potential to attenuate dopaminergic firing, quenching the reward and thus motivation associated with romantic love. caryophyllene 53-71 cannabinoid receptor 2 Homo sapiens 41-44 27234712-0 2016 beta-Caryophyllene attenuates palmitate-induced lipid accumulation through AMPK signaling by activating CB2 receptor in human HepG2 hepatocytes. caryophyllene 0-18 cannabinoid receptor 2 Homo sapiens 104-107 28624443-8 2017 TC is a specific agonist of the type 2 cannabinoid receptor (CB2R). caryophyllene 0-2 cannabinoid receptor 2 Homo sapiens 61-64 26965491-4 2016 RESULTS: BCP was found to elicit a full agonist action on cannabinoid type 2 (CB2) receptors, a G-protein coupled receptor representing important therapeutic target in several diseases. caryophyllene 9-12 cannabinoid receptor 2 Homo sapiens 78-81 24488604-2 2014 Given the fact that the activation of the type 2 cannabinoid receptor (CB2R) provides antioxidative and anti-inflammatory results, it is suspected that its selective agonist, trans-caryophyllene (TC), may have protective effects against hypoxia-induced neuroinflammatory responses. caryophyllene 175-194 cannabinoid receptor 2 Homo sapiens 71-74 24488604-2 2014 Given the fact that the activation of the type 2 cannabinoid receptor (CB2R) provides antioxidative and anti-inflammatory results, it is suspected that its selective agonist, trans-caryophyllene (TC), may have protective effects against hypoxia-induced neuroinflammatory responses. caryophyllene 196-198 cannabinoid receptor 2 Homo sapiens 71-74 24831513-1 2014 The widespread dietary plant sesquiterpene hydrocarbon beta-caryophyllene (1) is a CB2 cannabinoid receptor-specific agonist showing anti-inflammatory and analgesic effects in vivo. caryophyllene 55-73 cannabinoid receptor 2 Homo sapiens 83-86